| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02521051 | Non-Small Cell Lung Cancer (NSCLC) | Drug: Alectinib|Drug: Bevacizumab | Massachusetts General Hospital|Genentech, Inc. | Phase 1|Phase 2 | 2015-10-01 | 2016-09-12 |
| NCT02075840 | Non-Small Cell Lung Cancer | Drug: Alectinib|Drug: Crizotinib | Hoffmann-La Roche | Phase 3 | 2014-08-01 | 2017-02-23 |
| NCT02838420 | Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer | Drug: Alectinib|Drug: Crizotinib | Hoffmann-La Roche | Phase 3 | 2016-08-01 | 2016-11-01 |
| NCT02621047 | Hepatic Impairment | Drug: Alectinib | Hoffmann-La Roche | Phase 1 | 2015-12-01 | 2017-02-21 |
| NCT01984229 | Healthy Volunteer | Drug: Alectinib|Drug: Posaconazole | Hoffmann-La Roche | Phase 1 | 2013-12-01 | 2016-08-16 |
| NCT02023125 | Healthy Volunteer | Drug: Alectinib|Drug: Esomeprazole|Other: High Fat and Calorie Meal|Other: Standard Meal | Hoffmann-La Roche | Phase 1 | 2013-12-01 | 2016-08-16 |
| NCT02604342 | Non-small Cell Lung Cancer | Drug: Alectinib|Drug: Docetaxel|Drug: Pemetrexed | Hoffmann-La Roche | Phase 3 | 2015-11-03 | 2017-03-14 |
| NCT02271139 | Non-Small Cell Lung Cancer | Drug: Alectinib | Genentech, Inc. | | null | 2017-03-07 |
| NCT02013219 | Non-Small Cell Lung Cancer | Drug: Alectinib|Drug: Atezolizumab [TECENTRIQ]|Drug: Erlotinib | Hoffmann-La Roche | Phase 1 | 2014-04-03 | 2017-03-17 |
| NCT01871805 | Non-Small Cell Lung Cancer | Drug: RO5424802|Drug: RO5424802 | Hoffmann-La Roche | Phase 2 | 2013-09-01 | 2016-07-01 |
| NCT01981005 | Healthy Volunteer | Drug: RO5424802 | Hoffmann-La Roche | Phase 1 | 2013-11-01 | 2016-11-01 |
| NCT01940510 | Healthy Volunteer | Drug: RO5424802|Drug: rifampin | Hoffmann-La Roche | Phase 1 | 2013-10-01 | 2016-11-01 |
| NCT02074553 | Healthy Volunteer | Drug: Part 1 (Fasted): Treatment A|Drug: Part 1 (Fasted): Treatment B|Drug: Part 1 (Fasted): Treatment C|Drug: Part 1 (Fasted): Treatment D|Drug: Part 2 (Fed): Treatment A|Drug: Part 2 (Fed): Treatment B|Drug: Part 2 (Fed): Treatment C|Drug: Part 2 (Fed): Treatment D | Hoffmann-La Roche | Phase 1 | 2014-02-01 | 2016-08-25 |
| NCT01588028 | ALK-Rearranged Non-Small Cell Lung Cancer | Drug: CH5424802 | Hoffmann-La Roche | Phase 1 | 2012-04-01 | 2014-10-16 |
| NCT01801111 | Non-Squamous Non-Small Cell Lung Cancer | Drug: erlotinib [Tarceva]|Drug: RO5452802 | Hoffmann-La Roche | Phase 2 | 2013-06-01 | 2016-04-11 |
| NCT02450903 | Non-Small-Cell Lung Cancer | Drug: LDK378 | Novartis Pharmaceuticals|Novartis | Phase 2 | 2015-08-01 | 2017-02-05 |
| NCT02314481 | Non-small Cell Lung Cancer | Drug: MPDL3280A|Drug: Vemurafenib|Drug: Alectinib|Drug: Trastuzumab emtansine | University College, London|Hoffmann-La Roche | Phase 2 | 2017-01-01 | 2016-03-08 |
| NCT02706626 | Non-Small Cell Lung Cancer | Drug: brigatinib | Criterium, Inc.|University of Colorado, Denver|Duke University|Ariad Pharmaceuticals | Phase 2 | 2017-03-09 | 2017-03-10 |
| NCT03087448 | Non-small Cell Lung Cancer | Drug: Ceritinib|Drug: Trametinib | University of California, San Francisco|Novartis Pharmaceuticals|University of California, Davis|University of California, Los Angeles|University of California, San Diego|University of California, Irvine | Phase 1|Phase 2 | 2017-03-01 | 2017-03-16 |
| NCT01634763 | Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) | Drug: LDK378 | Novartis Pharmaceuticals|Novartis | Phase 1 | 2012-06-01 | 2016-07-25 |
